Evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy
Evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy
ClinicalTrials.gov ID: NCT05136456
Sponsor: Reistone Biopharma Company Limited
Information provided by: Reistone Biopharma Company Limited (Responsible Party)
Last Update Posted: 2023-09-05
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.
Detailed Description:
This study is a phase II study to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.
Official Title:
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN)
Intervention / Treatment:
- Drug: SHR1459 Low Dose
- Drug: SHR1459 High Dose
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) |
2021-12-15
|
| Primary Completion (Estimated) |
2023-08-28
|
| Study Completion (Estimated) |
2024-03-11
|
| Enrollment (Estimated) | 61 |
| Study Type | Interventional |
| Phase | Phase 2 |
| Other Study ID Numbers |
RSB20926
|